FACTORS OF ARTERIAL HYPERTENSION PROGRESSION IN PATIENTS IN COMORBIDITY WITH TYPE 2 DIABETES MELLITUS
Keywords:
arterial hypertension, diabetes mellitus, risk factor, microvascular complications, macrovascular complicationsAbstract
Patients with diabetes and hypertension are at increased risk of macrovascular and microvascular complications. To prevent and slow the progression of these complications, it is necessary to target multiple risk factors. It has been demonstrated that optimizing the control of glycemia, lipids and blood pressure improves patient outcomes. The benefits of optimal treatment of dyslipidemia with statins may become evident within a few months in high-risk patients, while significant reductions in cardiovascular risk from hyperglycemia and hypertension control develop over several years.
References
Ташкенбаева Э. Н. и др. АССОЦИИРОВАННЫЕ ФАКТОРЫ РИСКА КАРДИОВАСКУЛЯРНЫХ СОБЫТИЙ У ЖЕНЩИН В ПОСТМЕНОПАУЗАЛЬНОМ ПЕРИОДЕ //cardio. – 2020. – Т. 1. – №. 3.
Ташкенбаева Э. Н. и др. Предикторы развития сердечно-сосудистых осложнений у больных с острым инфарктом миокарда с подъемом сегмента ST //Наука и общество в эпоху перемен. – 2018. – №. 1. – С. 12-15.
ACCORD Study Group. Effects of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1575–85.
ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New Engl J Med. 2008;358:2560.
Antithrombotic Trialists’ (ATT) Collaboration. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009;373:1849–1860.
Ayerden EF, et al. The relationship between vascular endothelial growth factor (VEGF) and microalbuminuria in patients with essential hypertension. Intern Med. 2008;47(17):1511–6.
Brunzell JD, Davidson M, Furberg CD, et al. American Diabetes Association, American College of Cardiology Foundation. Lipoprotein management in patients with cardiometabolic risks: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31:811–822.
Centers for Disease Control and Prevention. National diabetes fact sheet 2010
Center for Disease Control of Prevention. SEARCH for Diabetes in Youth. [accessed November 13, 2010]. Available at: http://www.cdc.gov/diabetes/pubs/factsheets/search.htm#3.
Ceriello A, Ihnat MA, Thorpe JE. The ‘metabolic memory’: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab. 2009;94:410–415.
Ceriello A. Hyperglycemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes. Eur J Cardiovasc Prev Rehabil. 2010 May;17(1):S15–9.
Dagogo-Jack S. Primary prevention of cardiovascular disease in diabetic patients. Cardio Q. 2006;12:20.
de Boer IH, et al. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Arch Intern Med. 2008 Sep 22;168(17):1867–73.
Duckworth W, Abraira C, Moritz T, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129.
Estruch R, Martinez-Gonzalez MA, Corella D, et al. Effects of a Mediterranean-style diet on cardiovascular risk factors. A randomized trial. Ann Intern Med. 2006;145:1.
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effects of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–91.
Holman RR, Paul SK, Bethel MA, et al. 10 –year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577.
Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417.
Istamova S. S. et al. LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION IN COMORBID CONDITION //Euro-Asia Conferences. – 2021. – Т. 1. – №. 1. – С. 334-338.
Knopp RH, d’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN) Diabetes Care. 2006;29:1478–1485.
Patel A, MacMahon S, et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829.
Ranney L, Melvin C, Lux L, McClain E, Lohr KN. Systematic review: smoking cessation intervention strategies for adults and adults in special populations. Ann Intern Med. 2006 Dec 5;145:845–856.
Rasuli F. O. et al. Clinical features of ihd course on the background of atrial fibrillation //Euro-Asia Conferences. – 2021. – Т. 1. – №. 1. – С. 195-199.
Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195–207.
Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systemic review. JAMA. 2007;298:786–1485.
